Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Accumulated Expenses (2016 - 2025)

Kiora Pharmaceuticals' Accumulated Expenses history spans 11 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 47.55% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 47.55%, while the annual FY2025 figure was $2.4 million, 47.55% down from the prior year.
  • Accumulated Expenses reached $2.4 million in Q4 2025 per KPRX's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.6 million in Q4 2024 to a low of $336680.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $1.6 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: crashed 61.98% in 2022, then skyrocketed 285.69% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $1.3 million in 2021, then tumbled by 58.64% to $550133.0 in 2022, then skyrocketed by 150.97% to $1.4 million in 2023, then surged by 232.35% to $4.6 million in 2024, then crashed by 47.55% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Accumulated Expenses are $2.4 million (Q4 2025), $2.2 million (Q3 2025), and $2.5 million (Q2 2025).